Wall Street isn’t (yet) getting that ABT is the leader of the pack in all-oral HCV, at least for genotype-1. GILD and BMY are duking it out for the privilege of being #2, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”